文献速递特殊人群用药药物相互作用治疗药物监测与药物基因组学

妊娠期抗逆转录病毒暴露与药物相互作用的临床解读框架

Interpreting antiretroviral exposure and drug-drug interactions in pregnancy: A clinically anchored framework for HIV pharmacology.
PubMed 文献 · Br J Clin Pharmacol · 2026-10-28

该综述提出,妊娠期抗逆转录病毒药物相互作用应结合胃肠生理、蛋白结合、肾脏排泄、肝酶活性及膜转运体表达的变化来解读。暴露比值仅反映相对药代动力学变化,不能说明有效暴露是否维持;作者提出整合临床情境、活性成分、暴露指标、证据锚点、分布性靶达标和临床结局的六域框架。

要点

  • 妊娠期暴露比值仅描述相对变化,需判断有效暴露是否维持
  • 妊娠特异靶值缺乏时,可沿用经验证的一般暴露-反应靶值
  • 相似比例的暴露下降因治疗窗、耐药屏障和机制不同而临床意义不同

核心结论

  • 核心目标不是定义统一的妊娠期阈值,而是判断在妊娠生理和合并用药下是否维持药理学有效暴露。
  • 妊娠期抗逆转录病毒相互作用须结合胃肠生理、蛋白结合、肾排泄、肝酶及转运体动态变化解读。

研究设计与样本

  • 本综述评估候选证据锚点,包括经蛋白校正的体外抑制浓度、暴露-反应关系、治疗药物监测靶值和模型预测的靶达标概率。
  • 文中汇总整合酶抑制剂、蛋白酶抑制剂、非核苷类逆转录酶抑制剂、替诺福韦制剂和长效药物的证据。

主要发现

  • 相似比例的暴露下降可因治疗窗、耐药屏障、相互作用机制、制剂及药理学相关基质不同而产生不同临床意义。
  • 妊娠可改变受害抗逆转录病毒药和 perpetrator 药的药代动力学,从而影响靶达标与变异性。

关键数值与推荐

  • 妊娠特异靶值不可得时,经验证的暴露-反应靶值仍可作为合理起始锚点。
  • 无证据表明妊娠期免疫适应本身需要不同的内在抗病毒靶值。
  • 长效注射 PrEP 的保护性暴露、给药间隔和药代动力学拖尾需与治疗靶值分开考虑。

临床怎么用

  • 解读妊娠期相互作用研究时,应结合六域框架判断有效暴露是否维持,而非仅看几何均值暴露比。
  • 妊娠特异数据缺乏时,可用基于生理的药代动力学和群体药代动力学模型作为证据,但须考虑模型验证与不确定性。

局限性

  • 妊娠特异数据常缺乏,基于生理的药代动力学和群体药代动力学模型的使用应反映模型验证和不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In pregnancy, antiretroviral drug-drug interactions must be interpreted against dynamic changes in gastrointestinal physiology, plasma-protein binding, renal elimination, hepatic enzyme activity and membrane transporter expression. Interaction studies quantify geometric mean exposure ratios relative to nonpregnant adults, but these measures describe relative pharmacokinetic change rather than whether effective exposure is preserved. For HIV treatment, validated exposure-response targets remain reasonable starting anchors when pregnancy-specific targets are unavailable. No evidence indicates that gestational immune adaptation alone requires a different intrinsic antiviral target. Pregnancy alters target attainment by altering drug disposition and variability, and it can modify the pharmacokinetics of both the victim antiretroviral and the perpetrator drug. For long-acting injectable PrEP, protective exposure, dosing interval and pharmacokinetic tail require separate consideration from treatment targets. This review evaluates candidate evidentiary anchors, including protein-adjusted in vitro inhibitory concentrations, exposure-response relationships, therapeutic drug-monitoring targets and model-informed probability of target attainment. Evidence from integrase inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors, tenofovir formulations and long-acting agents demonstrates that similar proportional reductions in exposure can have different clinical implications depending on therapeutic margin, resistance barrier, interaction mechanism, formulation and pharmacologically relevant matrix. A newly proposed six-domain framework integrates clinical context, active analyte, exposure metric, evidentiary anchor, distributional target attainment and clinical outcomes. Physiologically based and population pharmacokinetic models provide evidence when pregnancy-specific data are unavailable, but their use should reflect model verification and uncertainty. The central objective is therefore not to define a universal pregnancy threshold but to determine whether pharmacologically effective exposure is maintained in the setting of gestational physiology and concomitant medicines.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Eke. Interpreting antiretroviral exposure and drug-drug interactions in pregnancy: A clinically anchored framework for HIV pharmacology. Br J Clin Pharmacol. 2026. PMID: 42951826. doi:10.1002/bcp.70863

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。